Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry, Sector and Symbol:

Sector: Medical
Industry: Bio Therapeutic Drugs
Sub-Industry: Biotechnology
Symbol: NASDAQ:VRTX
CUSIP: 92532F10
Web: www.vrtx.com

Capitalization:

Market Cap: $38.3372 billion
Outstanding Shares: 252,118,000

Average Prices:

50 Day Moving Avg: $154.59
200 Day Moving Avg: $128.57
52 Week Range: $71.46 - $167.85

P/E:

Trailing P/E Ratio: 145.30
Foreward P/E Ratio: 77.57
P/E Growth: 1.38

Sales & Book Value:

Annual Revenue: $2.13 billion
Price / Sales: 17.90
Book Value: $6.66 per share
Price / Book: 22.71

Profitability:

EBIDTA: $408.78 million
Net Margins: 12.05%
Return on Equity: 4.64%
Return on Assets: 2.41%

Debt:

Debt-to-Equity Ratio: 0.01%
Current Ratio: 3.49%
Quick Ratio: 3.34%

Misc:

Average Volume: 1.87 million shs.
Beta: 1.75
Short Ratio: 1.32

Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Wednesday, July, 26th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.33. The firm earned $544.10 million during the quarter, compared to analysts' expectations of $489.95 million. Vertex Pharmaceuticals Incorporated had a return on equity of 4.64% and a net margin of 12.05%. The firm's revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the business posted $0.24 earnings per share. View Vertex Pharmaceuticals Incorporated's Earnings History.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

24 equities research analysts have issued 12 month target prices for Vertex Pharmaceuticals Incorporated's shares. Their predictions range from $81.00 to $200.00. On average, they expect Vertex Pharmaceuticals Incorporated's share price to reach $162.96 in the next twelve months. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

1. According to Zacks Investment Research, "Vertex beat estimates for both earnings and sales in Q2 as sales of both its cystic fibrosis (CF) drugs rose. Vertex has two CF drugs in its portfolio with blockbuster potential – Kalydeco & Orkambi. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase patient population and boost sales. Vertex’s CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Investor focus is on the triple combination CF regimens, which are crucial for long-term growth as they have the potential to treat up to 90% of CF patients. We are encouraged by the recent positive data from three of the triple combination regimens. The stock has also shot up this year. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Orkambi’s EU reimbursement remains a key for sales growth in 2H17." (8/4/2017)
2. Cowen and Company analysts commented, "Vertex announced that the FDA has approved Kalydeco for use in CF patients over the." (8/1/2017)
3. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
4. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)

Who are some of Vertex Pharmaceuticals Incorporated's key competitors?

Some companies that are related to Vertex Pharmaceuticals Incorporated include Regeneron Pharmaceuticals (REGN), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), BIOVERATIV INC (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Spark Therapeutics (ONCE), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Axovant Sciences Ltd (AXON), Prothena Corporation PLC (PRTA) and China Biologic Products (CBPO).

Who are Vertex Pharmaceuticals Incorporated's key executives?

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
Paul M. Silva, Senior Vice President, Corporate Controller
Bruce I. Sachs, Lead Director, Independent Director
Elaine S. Ullian, Co-Lead Independent Director

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.70%), FMR LLC (7.33%), Vanguard Group Inc. (6.73%), Capital World Investors (6.11%), State Street Corp (4.51%) and JPMorgan Chase & Co. (3.32%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Ameriprise Financial Inc., JPMorgan Chase & Co., State Street Corp, HealthCor Management L.P., FMR LLC, Lazard Asset Management LLC and Laurion Capital Management LP. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Old Mutual Global Investors UK Ltd., AJO LP, Vanguard Group Inc., TIAA CREF Investment Management LLC, Fred Alger Management Inc., Janus Henderson Group PLC and Columbus Circle Investors. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals Incorporated's stock price today?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $151.26.

MarketBeat Community Rating for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		965 (Vote Outperform)
Underperform Votes:		525 (Vote Underperform)
Total Votes:		1,490

MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	3 Hold Ratings, 21 Buy Ratings
Consensus Rating:	Buy (Score: 2.88)
Consensus Price Target:	$162.96 (7.73% upside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$195.00	Low
9/14/2017	Royal Bank Of Canada	Initiated Coverage	Outperform -> Outperform	$175.00	Low
8/22/2017	Jefferies Group LLC	Reiterated Rating	Buy		High
8/1/2017	Cowen and Company	Reiterated Rating	Buy		Medium
8/1/2017	Argus	Boost Price Target	Buy	$71.46 -> $175.00	Low
7/27/2017	BMO Capital Markets	Reiterated Rating	Outperform	$180.00 -> $182.00	Low
7/27/2017	Oppenheimer Holdings, Inc.	Boost Price Target	Outperform	$150.00 -> $175.00	Medium
7/27/2017	J P Morgan Chase & Co	Set Price Target	Buy	$175.00 -> $184.00	High
7/27/2017	Maxim Group	Set Price Target	Buy	$195.00	High
7/22/2017	Morgan Stanley	Reiterated Rating	Overweight	$153.00 -> $190.00	Low
7/21/2017	Robert W. Baird	Reiterated Rating	Outperform	$136.00 -> $171.00	Low
7/21/2017	Citigroup Inc.	Reiterated Rating	Buy	$135.00 -> $190.00	Low
7/19/2017	Credit Suisse Group	Boost Price Target	Outperform	$125.00 -> $195.00	High
7/19/2017	JMP Securities	Reiterated Rating	Outperform		High
7/19/2017	Raymond James Financial, Inc.	Upgrade	Market Perform -> Outperform	$181.00	High
7/19/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$194.00	High
7/19/2017	HC Wainwright	Reiterated Rating	Hold	$85.00	High
7/19/2017	Janney Montgomery Scott	Upgrade	Neutral -> Buy	$98.00	High
7/19/2017	Barclays PLC	Upgrade	Equal Weight -> Overweight	$115.00 -> $180.00	High
7/18/2017	Stifel Nicolaus	Boost Price Target	Buy -> Buy	$130.00 -> $154.00	High
6/22/2017	Leerink Swann	Reiterated Rating	Outperform		Medium
6/2/2017	CIBC	Upgrade	Market Perform -> Outperform		Low
5/19/2017	Bank of America Corporation	Reiterated Rating	Neutral	$121.00 -> $125.00	Low
11/1/2016	William Blair	Downgrade	Outperform -> Market Perform	$105.00 -> $81.00	N/A
4/28/2016	Goldman Sachs Group, Inc. (The)	Downgrade	Buy -> Neutral	$109.00 -> $88.00	N/A
3/28/2016	Guggenheim	Lower Price Target	Buy	$145.00 -> $114.00	N/A

(Data available from 9/23/2015 forward)

Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/23/2017		$0.40					N/A
7/26/2017	Q2 2017	$0.06	$0.39	$489.95 million	$544.10 million	View	N/A
4/27/2017	Q1 2017	$0.04	$0.13	$692.64 million	$714.72 million	View	N/A
1/25/2017	Q4 2016	$0.29	$0.35	$453.40 million	$458.71 million	View	N/A
10/25/2016	Q316	$0.18	$0.16	$423.53 million	$413.78 million	View	Listen
7/27/2016	Q216	$0.21	$0.24	$428.08 million	$431.61 million	View	Listen
4/27/2016	Q116	$0.29	$0.09	$439.94 million	$398.10 million	View	Listen
1/27/2016	Q4	$0.17	$0.17	$406.30 million	$417.94 million	View	Listen
10/28/2015	Q315	($0.60)	($0.13)	$245.84 million	$309.82 million	View	Listen
7/29/2015	Q215	($0.58)	($0.54)	$149.49 million	$166.00 million	View	Listen
4/29/2015	Q115	($0.75)	($0.62)	$142.38 million	$138.51 million	View	Listen
1/28/2015	Q414	($0.65)	($0.55)	$137.50 million	$144.56 million	View	Listen
10/28/2014	Q314	($0.62)	($0.37)	$146.20 million	$179.00 million	View	N/A
7/29/2014	Q214	($0.71)	($0.61)	$131.85 million	$138.42 million	View	Listen
5/1/2014	Q114	($0.68)	($0.65)	$134.46 million	$118.50 million	View	N/A
1/29/2014	Q413	($0.49)	($0.56)	$221.08 million	$351.20 million	View	Listen
10/29/2013	Q413	($0.33)	($0.32)	$278.80 million	$222.00 million	View	N/A
7/29/2013	Q2 2013	($0.18)	($0.26)	$308.02 million	$310.80 million	View	N/A
4/30/2013	Q1 2013	($0.06)	$0.03	$307.85 million	$328.40 million	View	N/A
1/29/2013	Q4 2012	($0.07)	($0.35)	$318.53 million	$334.00 million	View	N/A
11/1/2012	Q312	$0.34	$0.13	$377.14 million	$336.00 million	View	N/A
7/30/2012		$0.68	$0.46			View	N/A
4/26/2012		$0.57	$0.43			View	N/A
2/2/2012		$0.76	$0.74			View	N/A
10/27/2011		$0.17	$0.70			View	N/A
7/28/2011		($1.00)	($0.67)			View	N/A
5/3/2011		($1.09)	($0.91)			View	N/A
2/3/2011		($0.93)	($0.74)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

2017 EPS Consensus Estimate: $0.56

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	4	($0.02)	$0.04	$0.02
Q2 2017	4	$0.02	$0.11	$0.07
Q3 2017	3	$0.07	$0.11	$0.09
Q4 2017	3	$0.26	$0.56	$0.38

(Data provided by Zacks Investment Research)

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/29/2013	quarterly	$0.40			2/20/2013	3/13/2013

(Data available from 1/1/2013 forward)

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 92.85%

Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/31/2017	David Altshuler	EVP	Sell	1,796	$160.00	$287,360.00
8/7/2017	Ian F Smith	CFO	Sell	4,250	$155.39	$660,407.50
8/7/2017	Paul M Silva	SVP	Sell	1,289	$152.88	$197,062.32
8/3/2017	Jeffrey Chodakewitz	CMO	Sell	5,390	$154.17	$830,976.30
8/3/2017	Michael Parini	EVP	Sell	2,330	$155.72	$362,827.60
8/2/2017	Ian F Smith	CFO	Sell	2,155	$154.17	$332,236.35
8/2/2017	Jeffrey Chodakewitz	CMO	Sell	1,796	$154.13	$276,817.48
8/2/2017	Paul M Silva	SVP	Sell	1,289	$151.80	$195,670.20
7/31/2017	Jeffrey M Leiden	CEO	Sell	11,063	$152.81	$1,690,537.03
7/31/2017	Paul M Silva	SVP	Sell	860	$152.99	$131,571.40
7/31/2017	Stuart A Arbuckle	EVP	Sell	2,125	$152.99	$325,103.75
7/21/2017	Amit Sachdev	EVP	Sell	28,625	$160.93	$4,606,621.25
7/21/2017	Ian F Smith	CFO	Sell	133,750	$160.98	$21,531,075.00
7/21/2017	Jeffrey Chodakewitz	CMO	Sell	46,733	$160.96	$7,522,143.68
7/21/2017	Jeffrey M Leiden	CEO	Sell	216,624	$160.96	$34,867,799.04
7/21/2017	Paul M Silva	SVP	Sell	43,443	$161.07	$6,997,364.01
7/19/2017	Michael Parini	EVP	Sell	10,829	$161.00	$1,743,469.00
7/17/2017	Jeffrey Chodakewitz	CMO	Sell	573	$129.85	$74,404.05
7/3/2017	Jeffrey Chodakewitz	CMO	Sell	3,438	$127.80	$439,376.40
6/21/2017	Jeffrey Chodakewitz	CMO	Sell	5,157	$132.87	$685,210.59
6/21/2017	Paul M Silva	SVP	Sell	2,577	$133.36	$343,668.72
6/5/2017	David Altshuler	EVP	Sell	7,500	$130.00	$975,000.00
6/2/2017	Jeffrey M Leiden	CEO	Sell	147,101	$129.50	$19,049,579.50
6/2/2017	Sangeeta N Bhatia	Director	Sell	1,176	$128.44	$151,045.44
6/2/2017	Stuart A Arbuckle	EVP	Sell	70,969	$128.06	$9,088,290.14
5/2/2017	Jeffrey Chodakewitz	CMO	Sell	8,979	$121.05	$1,086,907.95
4/28/2017	Jeffrey M Leiden	CEO	Sell	157,200	$119.50	$18,785,400.00
4/5/2017	Jeffrey Chodakewitz	CMO	Sell	8,021	$114.00	$914,394.00
4/3/2017	Jeffrey Chodakewitz	CMO	Sell	2,291	$108.85	$249,375.35
3/29/2017	Amit Sachdev	EVP	Sell	80,500	$107.63	$8,664,215.00
3/29/2017	Jeffrey Chodakewitz	CMO	Sell	13,750	$106.65	$1,466,437.50
3/29/2017	Paul M Silva	SVP	Sell	1,688	$106.30	$179,434.40
1/11/2017	Joshua S Boger	Director	Sell	8,000	$82.48	$659,840.00
1/4/2017	Joshua S Boger	Director	Sell	6,500	$77.13	$501,345.00
12/29/2016	Joshua S Boger	Director	Sell	6,500	$74.33	$483,145.00
12/21/2016	Joshua S Boger	Director	Sell	6,500	$74.16	$482,040.00
12/14/2016	Joshua S Boger	Director	Sell	6,500	$77.52	$503,880.00
11/30/2016	Joshua S Boger	Director	Sell	6,500	$83.48	$542,620.00
11/23/2016	Joshua S Boger	Director	Sell	6,500	$86.47	$562,055.00
11/16/2016	Joshua S Boger	Director	Sell	6,500	$91.55	$595,075.00
11/10/2016	Paul M Silva	SVP	Sell	5,062	$90.98	$460,540.76
11/9/2016	Joshua S Boger	Director	Sell	6,500	$90.98	$591,370.00
11/9/2016	Stuart A Arbuckle	EVP	Sell	1,208	$90.00	$108,720.00
11/2/2016	Joshua S Boger	Director	Sell	6,500	$77.75	$505,375.00
10/26/2016	Joshua S Boger	Director	Sell	6,500	$79.26	$515,190.00
10/19/2016	Joshua S Boger	Director	Sell	6,500	$81.84	$531,960.00
10/12/2016	Joshua S Boger	Director	Sell	6,500	$81.14	$527,410.00
10/5/2016	Joshua S Boger	Director	Sell	6,500	$87.44	$568,360.00
10/3/2016	Stuart A Arbuckle	EVP	Sell	1,208	$86.46	$104,443.68
9/28/2016	Joshua S Boger	Director	Sell	6,500	$88.15	$572,975.00
9/21/2016	Joshua S Boger	Director	Sell	6,500	$90.82	$590,330.00
9/14/2016	Joshua S Boger	Director	Sell	6,500	$92.37	$600,405.00
9/7/2016	Joshua S Boger	Director	Sell	6,500	$95.66	$621,790.00
8/31/2016	Joshua S Boger	Director	Sell	6,500	$94.62	$615,030.00
8/24/2016	Joshua S Boger	Director	Sell	7,500	$100.46	$753,450.00
8/22/2016	Joshua S Boger	Director	Sell	1,100	$100.79	$110,869.00
8/17/2016	Joshua S Boger	Director	Sell	6,900	$99.63	$687,447.00
8/11/2016	Joshua S Boger	Director	Sell	900	$100.19	$90,171.00
8/10/2016	Joshua S Boger	Director	Sell	7,100	$100.24	$711,704.00
8/3/2016	Joshua S Boger	Director	Sell	47,000	$100.66	$4,731,020.00
7/27/2016	Joshua S Boger	Director	Sell	6,500	$95.93	$623,545.00
7/20/2016	Joshua S Boger	Director	Sell	6,500	$90.33	$587,145.00
7/13/2016	Joshua S Boger	Director	Sell	6,500	$88.81	$577,265.00
7/6/2016	Joshua S Boger	Director	Sell	5,140	$88.99	$457,408.60
6/29/2016	Joshua S Boger	Director	Sell	5,130	$84.82	$435,126.60
6/22/2016	Joshua S Boger	Director	Sell	5,130	$86.61	$444,309.30
6/15/2016	Joshua S Boger	Director	Sell	5,130	$91.18	$467,753.40
6/8/2016	Joshua S Boger	Director	Sell	5,130	$94.95	$487,093.50
6/1/2016	Joshua S Boger	Director	Sell	5,130	$93.65	$480,424.50
5/25/2016	Joshua S Boger	Director	Sell	5,130	$89.09	$457,031.70
5/18/2016	Joshua S Boger	Director	Sell	5,130	$81.18	$416,453.40
5/16/2016	Amit Sachdev	EVP	Sell	117	$81.67	$9,555.39
5/16/2016	Ian F Smith	CFO	Sell	202	$82.06	$16,576.12
5/11/2016	Joshua S Boger	Director	Sell	5,130	$86.50	$443,745.00
5/9/2016	Paul M Silva	SVP	Sell	3,000	$87.63	$262,890.00
5/4/2016	Joshua S Boger	Director	Sell	5,130	$81.02	$415,632.60
4/27/2016	Joshua S Boger	Director	Sell	5,130	$83.67	$429,227.10
4/20/2016	Joshua S Boger	Director	Sell	5,130	$84.10	$431,433.00
4/13/2016	Joshua S Boger	Director	Sell	5,130	$84.27	$432,305.10
4/6/2016	Joshua S Boger	Director	Sell	5,130	$89.56	$459,442.80
3/30/2016	Joshua S Boger	Director	Sell	5,130	$78.83	$404,397.90
3/23/2016	Joshua S Boger	Director	Sell	5,130	$81.38	$417,479.40
3/16/2016	Joshua S Boger	Director	Sell	5,130	$79.65	$408,604.50
3/2/2016	Joshua S Boger	Director	Sell	5,130	$91.80	$470,934.00
2/24/2016	Joshua S Boger	Director	Sell	5,130	$85.25	$437,332.50
2/17/2016	Joshua S. Boger	Director	Sell	5,130	$86.93	$445,950.90
2/10/2016	Joshua S. Boger	Director	Sell	5,130	$82.57	$423,584.10
2/3/2016	Ian F. Smith	CFO	Sell	12,084	$90.84	$1,097,710.56
2/3/2016	Jeffrey M. Leiden	CEO	Sell	9,834	$90.82	$893,123.88
2/3/2016	Joshua S. Boger	Director	Sell	5,130	$90.81	$465,855.30
2/3/2016	Paul M. Silva	SVP	Sell	5,062	$90.82	$459,730.84
2/3/2016	Stuart A. Arbuckle	EVP	Sell	6,042	$90.82	$548,734.44
2/2/2016	Jeffrey Chodakewitz	CMO	Sell	2,375	$91.38	$217,027.50
1/27/2016	Joshua S. Boger	Director	Sell	11,200	$93.22	$1,044,064.00
1/20/2016	Joshua S. Boger	Director	Sell	10,400	$93.69	$974,376.00
1/13/2016	Joshua S. Boger	Director	Sell	10,400	$98.41	$1,023,464.00
1/6/2016	Joshua S. Boger	Director	Sell	10,400	$121.96	$1,268,384.00
1/4/2016	Yuchun Lee	Director	Sell	1,125	$122.21	$137,486.25
12/30/2015	Joshua S. Boger	Director	Sell	10,400	$127.15	$1,322,360.00
12/21/2015	Joshua S. Boger	Director	Sell	10,400	$119.26	$1,240,304.00
12/9/2015	Joshua S. Boger	Director	Sell	10,400	$120.80	$1,256,320.00
12/4/2015	Stuart A. Arbuckle	EVP	Sell	4,531	$123.98	$561,753.38
12/2/2015	Joshua S. Boger	Director	Sell	10,400	$130.91	$1,361,464.00
12/1/2015	David Altshuler	EVP	Sell	5,000	$131.00	$655,000.00
12/1/2015	Yuchun Lee	Director	Sell	1,125	$129.65	$145,856.25
11/23/2015	Joshua S. Boger	Director	Sell	10,400	$132.18	$1,374,672.00
11/11/2015	Joshua S. Boger	Director	Sell	10,400	$118.59	$1,233,336.00
11/4/2015	Joshua S. Boger	Director	Sell	10,400	$124.23	$1,291,992.00
11/2/2015	Yuchun Lee	Director	Sell	1,125	$126.19	$141,963.75
10/28/2015	Joshua S. Boger	Director	Sell	10,400	$119.01	$1,237,704.00
10/21/2015	Joshua S. Boger	Director	Sell	10,400	$108.82	$1,131,728.00
10/14/2015	Joshua S. Boger	Director	Sell	10,400	$112.62	$1,171,248.00
10/7/2015	Joshua S. Boger	Director	Sell	10,400	$109.61	$1,139,944.00
10/2/2015	Elaine Ullian	Director	Sell	20,000	$110.00	$2,200,000.00
10/1/2015	Stuart A. Arbuckle	EVP	Sell	12,417	$104.71	$1,300,184.07
10/1/2015	Yuchun Lee	Director	Sell	1,125	$104.64	$117,720.00
9/30/2015	Joshua S. Boger	Director	Sell	10,400	$103.14	$1,072,656.00
9/23/2015	Joshua S. Boger	Director	Sell	10,400	$111.89	$1,163,656.00
9/16/2015	Joshua S. Boger	Director	Sell	10,400	$133.24	$1,385,696.00
9/9/2015	Joshua S. Boger	Director	Sell	10,400	$131.41	$1,366,664.00
9/4/2015	Stuart A. Arbuckle	EVP	Sell	9,063	$125.77	$1,139,853.51
9/2/2015	Joshua S. Boger	Director	Sell	10,400	$125.85	$1,308,840.00
9/1/2015	Yuchun Lee	Director	Sell	1,125	$125.40	$141,075.00
8/26/2015	Joshua S. Boger	Director	Sell	10,400	$124.71	$1,296,984.00
8/19/2015	Joshua S. Boger	Director	Sell	10,400	$139.93	$1,455,272.00
8/12/2015	Joshua S Boger	Director	Sell	10,400	$135.83	$1,412,632.00
7/22/2015	Joshua S Boger	Director	Sell	10,400	$130.92	$1,361,568.00
7/15/2015	Joshua S Boger	Director	Sell	12,200	$133.98	$1,634,556.00
7/13/2015	Paul M Silva	SVP	Sell	1,125	$123.79	$139,263.75
7/8/2015	Joshua S Boger	Director	Sell	11,700	$122.74	$1,436,058.00
7/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$129.36	$296,363.76
7/1/2015	Joshua S Boger	Director	Sell	11,700	$125.60	$1,469,520.00
6/24/2015	Joshua S Boger	Director	Sell	11,700	$130.41	$1,525,797.00
6/17/2015	Joshua S Boger	Director	Sell	11,700	$123.90	$1,449,630.00
6/10/2015	Joshua S Boger	Director	Sell	11,700	$125.02	$1,462,734.00
5/20/2015	Joshua S Boger	Director	Sell	11,700	$126.73	$1,482,741.00
5/6/2015	Joshua S Boger	Director	Sell	11,700	$122.79	$1,436,643.00
5/5/2015	Paul M Silva	SVP	Sell	4,101	$123.68	$507,211.68
4/29/2015	Joshua S Boger	Director	Sell	11,700	$124.59	$1,457,703.00
4/27/2015	Paul M Silva	SVP	Sell	1,125	$129.74	$145,957.50
4/27/2015	Stuart A Arbuckle	EVP	Sell	61,480	$129.36	$7,953,052.80
4/27/2015	Terrence C Kearney	Director	Sell	68,125	$129.11	$8,795,618.75
4/22/2015	Joshua S Boger	Director	Sell	11,700	$132.46	$1,549,782.00
4/15/2015	Joshua S Boger	Director	Sell	11,700	$129.25	$1,512,225.00
4/13/2015	Paul M Silva	SVP	Sell	1,125	$128.60	$144,675.00
4/8/2015	Joshua S Boger	Director	Sell	11,700	$123.26	$1,442,142.00
4/6/2015	Margaret G Mcglynn	Director	Sell	12,500	$118.36	$1,479,500.00
4/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$115.50	$264,610.50
4/1/2015	Joshua S Boger	Director	Sell	11,700	$115.87	$1,355,679.00
3/25/2015	Joshua S Boger	Director	Sell	11,700	$120.76	$1,412,892.00
3/23/2015	Amit Sachdev	EVP	Sell	17,083	$132.28	$2,259,739.24
3/23/2015	Ian F Smith	CFO	Sell	6,042	$125.67	$759,298.14
3/23/2015	Paul M Silva	SVP	Sell	2,250	$125.65	$282,712.50
3/18/2015	Amit Sachdev	EVP	Sell	12,000	$130.00	$1,560,000.00
2/5/2015	Paul M Silva	SVP	Sell	1,688	$109.75	$185,258.00
2/4/2015	Joshua S Boger	Director	Sell	5,700	$108.81	$620,217.00
2/3/2015	Paul M Silva	SVP	Sell	2,063	$108.89	$224,640.07
2/2/2015	Jeffrey Chodakewitz	CMO	Sell	1,188	$109.60	$130,204.80
1/28/2015	Joshua S Boger	Director	Sell	10,688	$122.78	$1,312,272.64
1/26/2015	Paul M Silva	SVP	Sell	1,125	$125.62	$141,322.50
1/21/2015	Joshua S Boger	Director	Sell	10,500	$125.08	$1,313,340.00
1/14/2015	Joshua S Boger	Director	Sell	10,500	$120.16	$1,261,680.00
1/9/2015	Amit Sachdev	EVP	Sell	12,000	$125.00	$1,500,000.00
1/9/2015	Bruce I Sachs	Director	Sell	9,861	$125.04	$1,233,019.44
1/7/2015	Joshua S Boger	Director	Sell	10,500	$119.32	$1,252,860.00
1/2/2015	Jeffrey Chodakewitz	CMO	Sell	2,291	$122.54	$280,739.14
12/22/2014	Joshua S Boger	Director	Sell	10,500	$117.65	$1,235,325.00
12/17/2014	Joshua S Boger	Director	Sell	10,500	$110.66	$1,161,930.00
12/15/2014	Jeffrey M Leiden	CEO	Sell	50,017	$114.97	$5,750,454.49
12/12/2014	Paul M Silva	SVP	Sell	2,813	$120.08	$337,785.04
11/28/2014	Amit Sachdev	EVP	Sell	12,000	$120.00	$1,440,000.00
11/28/2014	Bruce I Sachs	Director	Sell	10,000	$120.03	$1,200,300.00
11/28/2014	Paul M Silva	SVP	Sell	8,164	$119.85	$978,455.40
11/26/2014	Joshua S Boger	Director	Sell	10,500	$114.54	$1,202,670.00
11/6/2014	Bruce I Sachs	Director	Sell	9,900	$115.21	$1,140,579.00
11/5/2014	Bruce I Sachs	Director	Sell	30,100	$112.62	$3,389,862.00
11/3/2014	Joshua S Boger	Director	Sell	127,411	$112.20	$14,295,514.20
10/29/2014	Joshua S Boger	Director	Sell	10,500	$109.44	$1,149,120.00
10/28/2014	Amit Sachdev	EVP	Sell	12,000	$115.00	$1,380,000.00
10/28/2014	David Altshuler	Director	Sell	2,000	$114.75	$229,500.00
10/28/2014	Jeffrey Chodakewitz	CMO	Sell	3,438	$115.00	$395,370.00
10/27/2014	Paul M Silva	SVP	Sell	1,125	$110.03	$123,783.75
10/13/2014	Paul M Silva	SVP	Sell	1,125	$107.89	$121,376.25
10/7/2014	Jeffrey Chodakewitz	CMO	Sell	3,436	$104.26	$358,237.36
10/6/2014	David Altshuler	Director	Sell	1,405	$109.75	$154,198.75
10/1/2014	Elaine Ullian	Director	Sell	5,000	$107.74	$538,700.00
10/1/2014	Stuart A Arbuckle	EVP	Sell	12,417	$107.71	$1,337,435.07
9/30/2014	Amit Sachdev	SVP	Sell	86,000	$112.68	$9,690,480.00
9/30/2014	Ian F Smith	CFO	Sell	108,026	$112.68	$12,172,369.68
9/30/2014	Jeffrey M Leiden	CEO	Sell	200,000	$112.69	$22,538,000.00
9/30/2014	Kenneth L Horton	EVP	Sell	36,000	$112.69	$4,056,840.00
9/29/2014	David Altshuler	Director	Sell	2,500	$114.75	$286,875.00
9/24/2014	Joshua S Boger	Director	Sell	5,200	$109.21	$567,892.00
9/19/2014	David Altshuler	Director	Sell	5,000	$102.25	$511,250.00
9/19/2014	Paul M Silva	SVP	Sell	25,408	$99.85	$2,536,988.80
9/19/2014	Stuart A Arbuckle	EVP	Sell	55,521	$100.00	$5,552,100.00
9/17/2014	Joshua S Boger	Director	Sell	5,200	$93.62	$486,824.00
9/10/2014	Joshua S Boger	Director	Sell	5,200	$94.42	$490,984.00
9/5/2014	David Altshuler	Director	Sell	2,500	$94.75	$236,875.00
9/3/2014	Joshua S Boger	Director	Sell	5,200	$92.79	$482,508.00
8/27/2014	Joshua S Boger	Director	Sell	5,200	$93.31	$485,212.00
8/20/2014	Joshua S Boger	Director	Sell	5,200	$91.51	$475,852.00
8/13/2014	Joshua S Boger	Director	Sell	5,200	$88.00	$457,600.00
8/6/2014	Joshua S Boger	Director	Sell	5,200	$86.54	$450,008.00
7/31/2014	David Altshuler	Director	Sell	5,000	$89.59	$447,950.00
7/31/2014	Paul M Silva	SVP	Sell	2,027	$88.97	$180,342.19
7/30/2014	Joshua S Boger	Director	Sell	5,200	$92.17	$479,284.00
7/15/2014	Wayne Joseph Riley	Director	Sell	4,800	$96.65	$463,920.00
7/1/2014	Elaine Ullian	Director	Sell	5,000	$95.21	$476,050.00
7/1/2014	Kenneth L Horton	EVP	Sell	30,134	$95.22	$2,869,359.48
6/24/2014	Megan E Pace	SVP	Sell	12,734	$98.03	$1,248,314.02
6/24/2014	Wayne Joseph Riley	Director	Sell	15,000	$98.03	$1,470,450.00
6/16/2014	Peter Mueller	EVP	Sell	7,500	$68.31	$512,325.00
6/9/2014	Elaine Ullian	Director	Sell	2,500	$75.00	$187,500.00
5/14/2014	Peter Mueller	EVP	Sell	7,500	$67.45	$505,875.00
5/2/2014	Megan Pace	SVP	Sell	1,000	$67.62	$67,620.00
4/15/2014	Peter Mueller	EVP	Sell	7,500	$61.63	$462,225.00
4/9/2014	Elaine Ullian	Director	Sell	2,500	$70.00	$175,000.00
3/21/2014	Bruce Sachs	Director	Sell	8,700	$74.59	$648,933.00
3/17/2014	Peter Mueller	EVP	Sell	7,500	$78.29	$587,175.00
2/7/2014	Jeffrey Leiden	CEO	Sell	35,944	$80.00	$2,875,520.00
1/22/2014	Bruce Sachs	Director	Sell	8,300	$84.47	$701,101.00
1/21/2014	Megan Pace	SVP	Sell	1,250	$85.00	$106,250.00
1/16/2014	Jeffrey Leiden	CEO	Sell	45,000	$80.00	$3,600,000.00
1/15/2014	Peter Mueller	EVP	Sell	7,500	$78.67	$590,025.00
12/23/2013	Bruce Sachs	Director	Sell	8,300	$73.02	$606,066.00
12/16/2013	Peter Mueller	EVP	Sell	7,500	$64.69	$485,175.00
12/12/2013	Jeffrey Leiden	CEO	Sell	9,834	$65.48	$643,930.32
12/12/2013	Kenneth Horton	EVP	Sell	4,532	$65.46	$296,664.72
12/12/2013	Megan Pace	SVP	Sell	5,083	$65.48	$332,834.84
12/4/2013	Joshua Boger	Director	Sell	1,400	$67.48	$94,472.00
11/25/2013	Joshua Boger	Director	Sell	1,400	$66.89	$93,646.00
11/20/2013	Bruce Sachs	Director	Sell	8,300	$65.28	$541,824.00
11/19/2013	Joshua Boger	Director	Sell	1,400	$62.31	$87,234.00
11/5/2013	Joshua Boger	Director	Sell	1,400	$65.64	$91,896.00
10/29/2013	Joshua S Boger	Director	Sell	1,400	$75.42	$105,588.00
10/29/2013	Thomas Connolly	SVP	Sell	1,688	$75.04	$126,667.52
10/24/2013	Bruce I Sachs	Director	Sell	8,300	$77.06	$639,598.00
10/23/2013	Joshua S Boger	Director	Sell	1,400	$76.77	$107,478.00
10/16/2013	Joshua S Boger	Director	Sell	1,400	$75.41	$105,574.00
10/15/2013	Peter Mueller	EVP	Sell	7,500	$73.25	$549,375.00
10/14/2013	Paul Silva	SVP	Sell	1,593	$71.87	$114,488.91
10/9/2013	Joshua Boger	Director	Sell	1,400	$72.35	$101,290.00
9/25/2013	Joshua Boger	Director	Sell	1,400	$74.72	$104,608.00
9/18/2013	Joshua Boger	Director	Sell	1,400	$77.43	$108,402.00
9/16/2013	Peter Mueller	EVP	Sell	7,500	$77.22	$579,150.00
9/11/2013	Joshua Boger	Director	Sell	1,400	$79.61	$111,454.00
9/4/2013	Joshua Boger	Director	Sell	1,400	$75.45	$105,630.00
8/29/2013	Bruce Sachs	Director	Sell	8,300	$77.19	$640,677.00
8/28/2013	Joshua Boger	Director	Sell	1,400	$76.24	$106,736.00
8/21/2013	Joshua Boger	Director	Sell	1,400	$76.96	$107,744.00
8/15/2013	Peter Mueller	EVP	Sell	7,500	$77.41	$580,575.00
8/14/2013	Joshua Boger	Director	Sell	1,400	$77.18	$108,052.00
8/7/2013	Joshua Boger	Director	Sell	1,400	$77.84	$108,976.00
8/5/2013	Paul Silva	SVP	Sell	3,001	$78.90	$236,778.90
7/31/2013	Joshua S Boger	Director	Sell	1,400	$80.89	$113,246.00
7/29/2013	Wayne Joseph Riley	Director	Sell	9,800	$80.09	$784,882.00
7/25/2013	Paul M Silva	SVP	Sell	1,125	$86.49	$97,301.25
7/24/2013	Bruce I Sachs	Director	Sell	8,300	$85.50	$709,650.00
7/19/2013	Amit Sachdev	SVP	Sell	22,250	$88.69	$1,973,352.50
7/18/2013	Joshua S Boger	Director	Sell	1,400	$86.12	$120,568.00
7/16/2013	Paul M Silva	SVP	Sell	2,063	$86.25	$177,933.75
7/15/2013	Christiana Stamoulis	SVP	Sell	1,125	$86.35	$97,143.75
7/15/2013	Peter Mueller	EVP	Sell	7,500	$86.34	$647,550.00
7/12/2013	Megan E Pace	SVP	Sell	10,678	$85.00	$907,630.00
7/11/2013	Joshua S Boger	Director	Sell	1,400	$83.83	$117,362.00
7/8/2013	Kenneth L Horton	EVP	Sell	1,813	$80.72	$146,345.36
7/8/2013	Megan E Pace	SVP	Sell	28,703	$80.89	$2,321,785.67
7/5/2013	Christiana Stamoulis	SVP	Sell	4,687	$81.21	$380,631.27
7/3/2013	Joshua S Boger	Director	Sell	1,400	$80.20	$112,280.00
7/2/2013	Peter Mueller	EVP	Sell	122,300	$79.80	$9,759,540.00
6/26/2013	Joshua S Boger	Director	Sell	1,400	$78.59	$110,026.00
6/21/2013	Bruce I Sachs	Director	Sell	8,300	$75.93	$630,219.00
6/19/2013	Joshua S Boger	Director	Sell	1,400	$79.11	$110,754.00
6/12/2013	Joshua S Boger	Director	Sell	1,400	$81.19	$113,666.00
6/5/2013	Joshua S Boger	Director	Sell	1,400	$77.15	$108,010.00
5/30/2013	Joshua S Boger	Director	Sell	1,400	$82.47	$115,458.00
5/22/2013	Joshua S Boger	Director	Sell	1,400	$79.72	$111,608.00
5/15/2013	Joshua S Boger	Director	Sell	1,400	$79.36	$111,104.00
5/14/2013	Bruce I Sachs	Director	Sell	60,000	$81.15	$4,869,000.00
12/26/2012	Joshua S Boger	Director	Sell	4,000	$41.86	$167,440.00
11/7/2012	Margaret G Mcglynn	Director	Buy	1,000	$45.50	$45,500.00
10/8/2012	Ian F Smith	CFO	Sell	44,787	$60.00	$2,687,220.00
10/3/2012	Joshua S Boger	Director	Sell	4,000	$57.74	$230,960.00
9/5/2012	Joshua S Boger	Director	Sell	4,000	$54.70	$218,800.00

(Data available from 1/1/2013 forward)

Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Source:

Date	Headline
	Vertex's Rocky September Causes Vetr To Urge Sell finance.yahoo.com - September 23 at 10:53 AM
	Vertex to Present at the Leerink Partners Roundtable Series on September 27 finance.yahoo.com - September 23 at 10:53 AM
	Vertex Pharmaceuticals: Going From 'Crisis' To Blockbuster finance.yahoo.com - September 23 at 10:53 AM
	Vertex Pharmaceuticals Incorporated (VRTX) Downgraded to "Sell" at Vetr Inc. www.americanbankingnews.com - September 21 at 7:35 PM
	Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference finance.yahoo.com - September 19 at 3:27 PM
	The Zacks Analyst Blog Highlights: iShares Core S&P 500 ETF, Vertex Pharmaceuticals, Align Technology, NRG Energy and Activision Blizzard finance.yahoo.com - September 19 at 9:26 AM
	Needham & Company LLC Reaffirms Buy Rating for Vertex Pharmaceuticals Incorporated (VRTX) www.americanbankingnews.com - September 17 at 8:58 AM
	Vertex Pharmaceuticals Incorporated (VRTX) Earns Outperform Rating from Analysts at Royal Bank Of Canada www.americanbankingnews.com - September 14 at 5:26 PM
	Deep Dive: Analysts have raised, or lowered, their price targets the most on these U.S. stocks www.marketwatch.com - September 14 at 7:32 AM
	Analysts have raised, or lowered, their price targets the most on these U.S. stocks finance.yahoo.com - September 12 at 12:01 PM
	Vertex Pharmaceuticals Incorporated (VRTX) Expected to Post Quarterly Sales of $512.50 Million www.americanbankingnews.com - September 12 at 11:36 AM
	2 Views on Vertex Pharmaceuticals Stock: Short Term vs. Long Term www.fool.com - September 12 at 8:18 AM
	Brokerages Expect Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Earnings of $0.35 Per Share www.americanbankingnews.com - September 10 at 2:40 PM
	Vertex to Present at the Morgan Stanley Healthcare Conference on September 11 finance.yahoo.com - September 8 at 10:06 AM
	Vertex Pharmaceuticals Could Be Headed Higher Once Again finance.yahoo.com - September 7 at 11:00 AM
	Top Biotech Stock Near Buy Zone After FDA Drug Approval finance.yahoo.com - September 7 at 11:00 AM
	Vertex Pharma (VRTX) Names Ironwood (IRWD) CFO Tom Graney as its New CFO - StreetInsider.com www.streetinsider.com - September 6 at 10:05 AM
	Behind Bioverativ’s Analyst Recommendations This September finance.yahoo.com - September 6 at 10:05 AM
	Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer finance.yahoo.com - September 6 at 10:05 AM
	Vertex Pharma surges 1% after news of new CFO finance.yahoo.com - September 6 at 10:05 AM
	Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells $287,360.00 in Stock www.americanbankingnews.com - September 5 at 8:06 PM
	3 Growth Stocks for the 21st Century www.fool.com - September 5 at 3:59 PM
	Vertex Pharmaceuticals Incorporated (VRTX) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - September 5 at 8:54 AM
	4 Biotech Stocks That More Than Doubled This Year finance.yahoo.com - September 2 at 10:19 AM
	How Vertex Pharmaceuticals Performed in 2Q17 finance.yahoo.com - September 1 at 10:55 AM
	Vertex Saw Successful Results from VX-440 Phase 2 Study finance.yahoo.com - September 1 at 10:55 AM
	Vertex Presented Successful Results for Cystic Fibrosis Treatment finance.yahoo.com - September 1 at 10:55 AM
	How Are Orkambi and Kalydeco Positioned after 2Q17? finance.yahoo.com - September 1 at 10:55 AM
	VRTX Stock: 3 Reasons to Be Cautious on Vertex Pharmaceuticals ... - Investorplace.com investorplace.com - August 30 at 8:53 PM
	Vertex Combo Treatments Continue To Advance - Seeking Alpha seekingalpha.com - August 30 at 8:53 PM
	Vertex Pharmaceuticals (VRTX) Down 5.2% Since Earnings Report: Can It Rebound? finance.yahoo.com - August 30 at 10:57 AM
	3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock investorplace.com - August 29 at 2:18 PM
	Vertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors - Investorplace.com investorplace.com - August 29 at 9:31 AM
	Vertex Pharmaceuticals Incorporated (VRTX) Stock Could Burn Investors investorplace.com - August 29 at 5:15 AM
	Vertex's Cystic Fibrosis Combo Gets Priority Review in US - Nasdaq www.nasdaq.com - August 25 at 12:26 PM
	Vertex Pharma (VRTX) Announces Acceptance of its Applications for Review of Tezacaftor/Ivacaftor Combination ... - StreetInsider.com www.streetinsider.com - August 25 at 12:26 PM
	Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA finance.yahoo.com - August 25 at 12:26 PM
	Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S. finance.yahoo.com - August 25 at 12:26 PM
	$511.72 Million in Sales Expected for Vertex Pharmaceuticals Incorporated (VRTX) This Quarter www.americanbankingnews.com - August 24 at 1:04 AM
	Lab-made "mini organs" helping doctors treat cystic fibrosis finance.yahoo.com - August 23 at 11:45 PM
	Commit To Buy Vertex Pharmaceuticals At $100, Earn 4.5% Using Options www.nasdaq.com - August 23 at 6:43 PM
	Market Close Report: NASDAQ Composite index closes at 6297.48 up 84.35 points - Nasdaq www.nasdaq.com - August 23 at 1:41 PM
	Lab-made "mini organs" helping doctors treat cystic fibrosis finance.yahoo.com - August 23 at 1:41 PM
	Vertex Pharmaceuticals Incorporated (VRTX) Expected to Post Earnings of $0.35 Per Share www.americanbankingnews.com - August 23 at 12:08 AM
	VRTX Stock: Vertex Pharmaceuticals Incorporated (VRTX) Stock Is ... - Investorplace.com investorplace.com - August 22 at 7:46 AM
	Vertex Pharmaceuticals Incorporated (VRTX) Downgraded by BidaskClub to Hold www.americanbankingnews.com - August 19 at 2:44 PM
	3 Stocks That Could Put Alibaba's Returns to Shame www.fool.com - August 16 at 8:28 AM
	ETFs with exposure to Vertex Pharmaceuticals, Inc. : August 15, 2017 finance.yahoo.com - August 15 at 8:47 PM
	Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn't Worth the Risk - Investorplace.com investorplace.com - August 15 at 8:07 AM
	Why Vertex Pharmaceuticals Incorporated (VRTX) Stock Isn’t Worth the Risk investorplace.com - August 14 at 11:35 AM